Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "An HIV/AIDS Prophylactic vaccine is possible"

Journal of Immune Based Therapies and Vaccines Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: An HIV/AIDS Prophylactic vaccine is possible. | Journal of Immune Based Therapies and Vaccines Review An HIV AIDS Prophylactic vaccine is possible Qiu Zhong and Ronald B Luftig BioMed Central Open Access Address Department of Microbiology Immunology and Parasitology Louisiana State University Health Sciences Center New Orleans LA USA Email Qiu Zhong - qzhong@lsuhsc.edu Ronald B Luftig - rlufti@lsuhsc.edu Corresponding authors Published 19 December 2007 Received 6 December 2007 Journal of Immune Based Therapies and Vaccines 2007 5 12 doi l0.ll86 l 476-8518-5- Accepted 19 December 2007 12 This article is available from http www.jibtherapies.cOm content 5 1 12 2007 Zhong and Luftig licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract One needs to think outside of the box as one of us Ronald B Luftig learned from many years as a mathematician and a biophysicist. In this short Review the need to focus on producing high levels of neutralizing antibodies NAbs to incoming and conformationally altered virus after it has bound to CD4 cells is essential. Increasing the number of gp120 molecules on the surface of L-2 particles could allow for an enhanced number of NAbs. The attempt at increasing CD8 T cell responses in recent vaccine trials has not worked perhaps because it may have allowed HIV to enter into remote sanctuaries. Our approach focuses on increasing NAbs before high levels of CD8 T cells are produced. Background It has now become a frequent ritual to read of the newest clinical trial failure and yet the same paradigm goes on 1 . Most recently the promising Phase III trial termed STEP started in December 2004 was stopped 2 . The strategy was to boost killer T-cells in .